FDA’s Fast Track Designation for Liafensine: A New Era in Treatment-Resistant Depression

FDA’s Fast Track Designation for Liafensine: A New Era in Treatment-Resistant Depression In a significant stride towards addressing the challenges posed by treatment-resistant depression (TRD), Denovo Biopharma LLC has received the coveted fast track designation from the U.S. Food and Drug Administration (FDA) for their promising drug, DB104, also known as liafensine. This decision underscores […]